These data are also in agreement with the current knowledge that anti-platelet is considered to be a part of cancer adjuvant therapy (Mezouar et al., 2016). Targeting PDGF alpha-receptor effectively counteracts skeletal metastases in PCa mice (Russell et al., 2010). High expression of PDGF alpha-receptor activation is associated with bone metastases in castration-resistant PCa (Russell et al., 2010). The platelet-derived growth factor (PDGF) proteins are potent stimulators of cell proliferation/transformation in PCa (Ustach et al., 2004). Numerous studies have identified enhanced platelet activation occurred in PCa. The mechanisms underlying the association of MPV and PDW with PCa are currently unclear. In addition, PSA, MPV, and PDW in combination significantly enhance the ability to distinguish PCa from BPH. Our study showed that PSA, and PDW are markedly higher and MPV is significantly reduced in PCa patients than in BPH patients. The aim of the current study was to determine the ability of PSA, MPV, and PDW, individually or in combination, to distinguish PCa from BPH. Platelet distribution width (PDW), another platelet parameter, indicates variation in platelet size and differentially diagnoses thrombocytopenia (Kaito et al., 2005).Ĭombination of several biomarkers for early detection may lead to enhanced sensitivities and specificities. Mean platelet volume (MPV) is a marker of activated platelets and is associated with gastric cancer, ovarian cancer, lung cancer, colon cancer, and breast cancer (Gu et al., 2015 Kemal et al., 2014 Kilincalp et al., 2014 Kumagai et al., 2015 Li et al., 2014).
There is, therefore, an urgent need for novel biomarkers that can effectively distinguish PCa from BPH.Īctivated platelets play a critical role in cancer progression and metastasis (Bambace and Holmes, 2011 Goubran et al., 2014). More, PSA levels are frequently elevated in benign prostatic hyperplasia (BPH). Although use of the prostate specific antigen (PSA) as a diagnostic marker has improved the detection of PCa, its low sensitivity and specificity for PCa makes early finding of PCa difficult. Prostate cancer (PCa) represents the second most commonly diagnosed malignancy and the sixth leading cause for cancer related death among men worldwide(Jemal et al.,2010).
0 kommentar(er)
